Significantly Less Discomfort Versus Vaginally Administered Capsules¹

Study design: Results of a prospective, randomized trial of 126 women receiving progesterone for IVF-ET or ICSI cycles. Patients received Crinone 8% (90 mg QD) or progesterone capsules used vaginally (200 mg TID). In both groups, progesterone support began on the evening before embryo transfer and continued until menstrual bleeding occurred or there was a positive pregnancy test. Patients who became pregnant received Gravibinon® (2 mL IM [250 mg 17OHP + 5 mg estradiol valerate]) BIW for 10 additional weeks or until an abortion occurred. Shown above are patient preference data (mean scores) from a questionnaire asking 47 randomly selected nonpregnant patients about aspects of comfort during luteal phase support after IVF-ET or ICSI cycles.

Utrogest® is manufactured by Dr. Kade Pharmazeutische Fabrik GmbH. This product is marketed in the United States by Solvay Pharmaceuticals, Inc., as Prometrium®.

Gravibinon is a registered trademark of Schering AG.

Reference: 1. Ludwig M, Schwartz P, Babahan B, et al. Luteal phase support using either Crinone® 8% or Utrogest®: results of a prospective, randomized study. Eur J Obstet Gynecol Reprod Biol. 2002;103:48–52.